Hodgkin's disease in HIV

Research output: Contribution to journalArticle

Abstract

The outcome of patients with HIV-HD has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs (ie, protease inhibitors), in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HD with chemotherapy. In fact, the possibility of reducing viral load to undetectable levels and increasing the CD4+ cell count reduces the risk of OIs during antineoplastic treatment. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HD may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. Finally, more effective antineoplastic regimens - such as high-dose chemotherapy with autologous stem cell transplantation (which is required in the case of HIV-HD, due to its aggressiveness) - should be considered to improve the response rate and disease-free survival of these patients.

Original languageEnglish
Pages (from-to)843-858
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume17
Issue number3
Publication statusPublished - Jun 2003

Fingerprint

Hodgkin Disease
Antineoplastic Agents
HIV
Drug Therapy
Stem Cell Transplantation
CD4 Lymphocyte Count
Protease Inhibitors
Viral Load
Nucleosides
Pharmaceutical Preparations
Disease-Free Survival
HIV Infections
Intercellular Signaling Peptides and Proteins
Therapeutics
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Hodgkin's disease in HIV. / Spina, Michele; Berretta, Massimiliano; Tirelli, Umberto.

In: Hematology/Oncology Clinics of North America, Vol. 17, No. 3, 06.2003, p. 843-858.

Research output: Contribution to journalArticle

@article{03a78fb8624b4210b88f806675539eb0,
title = "Hodgkin's disease in HIV",
abstract = "The outcome of patients with HIV-HD has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs (ie, protease inhibitors), in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HD with chemotherapy. In fact, the possibility of reducing viral load to undetectable levels and increasing the CD4+ cell count reduces the risk of OIs during antineoplastic treatment. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HD may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. Finally, more effective antineoplastic regimens - such as high-dose chemotherapy with autologous stem cell transplantation (which is required in the case of HIV-HD, due to its aggressiveness) - should be considered to improve the response rate and disease-free survival of these patients.",
author = "Michele Spina and Massimiliano Berretta and Umberto Tirelli",
year = "2003",
month = "6",
language = "English",
volume = "17",
pages = "843--858",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hodgkin's disease in HIV

AU - Spina, Michele

AU - Berretta, Massimiliano

AU - Tirelli, Umberto

PY - 2003/6

Y1 - 2003/6

N2 - The outcome of patients with HIV-HD has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs (ie, protease inhibitors), in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HD with chemotherapy. In fact, the possibility of reducing viral load to undetectable levels and increasing the CD4+ cell count reduces the risk of OIs during antineoplastic treatment. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HD may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. Finally, more effective antineoplastic regimens - such as high-dose chemotherapy with autologous stem cell transplantation (which is required in the case of HIV-HD, due to its aggressiveness) - should be considered to improve the response rate and disease-free survival of these patients.

AB - The outcome of patients with HIV-HD has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs (ie, protease inhibitors), in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HD with chemotherapy. In fact, the possibility of reducing viral load to undetectable levels and increasing the CD4+ cell count reduces the risk of OIs during antineoplastic treatment. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HD may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. Finally, more effective antineoplastic regimens - such as high-dose chemotherapy with autologous stem cell transplantation (which is required in the case of HIV-HD, due to its aggressiveness) - should be considered to improve the response rate and disease-free survival of these patients.

UR - http://www.scopus.com/inward/record.url?scp=0037710696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037710696&partnerID=8YFLogxK

M3 - Article

C2 - 12852658

AN - SCOPUS:0037710696

VL - 17

SP - 843

EP - 858

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -